Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria

Table 3 Clinical characteristics of PNH patients at baseline

Variable	Began trial on eculizumab (n = 219)				Began trial on ravulizumab (n = 222)
	Trial 301		Trial 302		Trial 301		Trial 302
	#	%	#	%	#	%	#	%
Observed LDH Category
LDH < 1.5×ULN	0	0	98	100	0	0	97	100
LDH 1.5–< 3×ULN	16	13	0	0	18	14	0	0
LDH ≥ 3×ULN	105	87	0	0	107	86	0	0
Observed pRBC stratum
0 unit pRBC	21	17	NA		22	18	NA
1–14 units pRBC	76	63			80	64
> 14 units pRBC	24	20			23	18
Immuno-suppressant treatment	14	12	98	100	15	12	97	100
Aplastic anemia	38	31	39	40	41	33	34	35
Myelodysplastic syndrome	6	5	6	6	7	6	3	3
Bone marrow disorder	43	36	42	43	46	37	35	36
Derived PNH risk-factor group
Higher	107	88	0	0	110	88	0	0
Lower	14	12	98	100	15	12	97	100

	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Derived PNH risk-factor index	9.21	0.93	6.46	0.56	9.22	0.87	6.38	0.53

ISSN: 1750-1172